SUMMARYInfluenza A virus was discovered in 1933, and since then four major variants have caused all the epidemies of human influenza A. Each had an era of solo world prevalence until 1977 as follows: H0N1 (old style) strains until 1946. H1N1 (old style) strains until 1957, H2N2 strains until 1968. then H3N2 strains, which were joined in 1977 by a renewed prevalence of H1N1 (old style) strains.Serological studies show that H2N2 strains probably had had a previous era of world prevalence during the last quarter of the nineteenth century, and had then been replaced by H3N2 strains from about 1900 to 1918. From about 1907 the H3N2 strains had been joined, as now. by H1N1 (old style) strains until both had been replaced in 1918 by a fifth major variant closely related to swine influenza virus A/Hswine1N1 (old style), which had then had an era of solo world prevalence in mankind until about 1929. when it had been replaced by the H0N1 strains that were first isolated in 1933.Eras of prevalence of a major variant have usually been initiated by a severe pandemic followed at intervals of a year or two by successive epidemics in each of which the nature of the virus is usually a little changed (antigenic drift), but not enough to permit frequent recurrent infections during the same era. Changes of major variant (antigenic shift) are large enough to permit reinfection. At both major and minor changes the strains of the previous variant tend to disappear and to be replaced within a single season, worldwide in the case of a major variant, or in the area of prevalence of a previous minor variant.Pandemics, epidemics and antigenic variations all occur seasonally, and influenza and its viruses virtually disappear from the population of any locality between epidemics, an interval of many consecutive months. A global view, however, shows influenza continually present in the world population, progressing each year south and then north, thus crossing the equator twice yearly around the equinoxes, the tropical monsoon periods. Influenza arrives in the temperate latitudes in the colder months, about 6 months separating its arrival in the two hemispheres.None of this behaviour is explained by the current concept that the virus is surviving like measles virus by direct spread from the sick providing endless chains of human influenza A. A number of other aspects of the human host influenza A virus relationship encountered in household outbreaks are among the list of 20 difficulties that are inexplicable by the current concept of direct spread.Alternative concepts have usually been designed to counter particular difficulties and are incompatible with other features of influenzal behaviour in mankind. The new concept detailed in the appendix provides simple explanations for most if not all of the difficulties. It proposes that influenza A virus cannot normally be transmitted during the illness because it too rapidly becomes non-infectious in a mode of persistence or latency in the human host. Many months or a year or two later it is reactivated by a seasonally mediated stimulus which, like all seasonal phenomena, is ultimately dependent on variations in solar radiation caused by the tilt of the plane of earth's rotation in relation to that of its circumsolar orbit. The carriers, who are always widely seeded throughout the world population, become briefly infectious and their non-immune companions, if infected, comprise the whole of the next epidemic. The reactivated virus particles must encounter the immunity they have engendered in the carrier, thus allowing minor mutants an advantage over virions identical with the parent virus, and so favouring antigenic drift and automatic disappearance of predecessor and prompt seasonal replacement. Antigenic shift and recycling of major variants may also be explained by virus latency in the human host.

HIV is a human lentivirus that infects CD4-positive immune cells and, when left untreated, manifests in the fatal disease known as AIDS. Antiretroviral therapy (ART) does not leading to viral clearance, and HIV persists in the organism as a latent provirus.

SUMMARYIn April-May 1980, two independent outbreaks of influenza-like illness occurred in Leningrad among children's-home children aged from 3 months to 2 years (of 68 children under observation, 50 became ill) and among boarding-school pupils aged 15–17 years (of 50 pupils under observation, 13 became ill).A total of five influenza A virus strains were derived from one clinically healthy and three affected children of the children's home. Similar viruses were obtained from one affected boarding-school pupil and from an infected woman aged 24 years (a sporadic case within a household). On the basis of laboratory findings, all these seven strains were identified as influenza A H2N2 subtype strains.Six of the affected children showed significant seroconversion only to H2 haemagglutinin from February to May 1980. Type A influenza H2N2 virus was isolated from three persons, including the sporadic case, who also showed significant seroconversion to H2 haemagglutinin. H2N2 influenza A virus was isolated on two occasions, at a 7-day interval, from the girl N. Ju.Laboratory findings obtained from the study of the viruses isolated using up-to-date immunological and molecular-biochemical techniques enable us to conclude the following. The A/Leningrad/80 isolates belong to H2N2 sero-subtype. The viruses isolated are similar but not identical to the A/Singapore/I/57 reference strain in details of polypeptide and gene composition.

No abstract

Previous studies suggest that short peptides from the heptad repeat 2 (HR2) domain of gp41 expressed on the cell surface are more potent inhibitors of HIV-1 entry than soluble analogs. However, their therapeutic potential has only been examined using lentiviral vectors. Here, we aimed to develop CRISPR/Cas9-based fusion inhibitory peptide knock-in (KI) technology for the generation and selection of HIV-1-resistant T cells. First, we cloned a series of HIV-1 fusion inhibitory peptides and embedded them in CD52, the shortest GPI-anchored protein, which efficiently delivers epitope tags to the cell surface and maintains a sufficient level of KI. Among the seven peptides tested, MT-C34, HP-23L, and 2P23 exhibited significant activity against both cell-free and cell-to-cell HIV-1 infection. Unlike membrane-bound peptides, the shed variant of MT-C34 provided insufficient protection against HIV-1 due to its low concentrations in the culture medium. Using Cas9 plasmids or ribonucleoprotein electroporation and cell sorting with antibodies raised against gp41 peptides, we generated CEM/R5 cells with biallelic KI of MT-C34 (embedded in CD52 for expression in lipid rafts) and 2P23 (N-terminally fused to CXCR4). In combination, these peptides provided a higher level of protection than individual KI. By extending homology arms and substituting PCR donor DNA with a plasmid containing signals for nuclear localization, we achieved KI of MT-C34 into CXCR4 loci and HIV-1 proviral DNA at levels of up to 35% in CEM/R5 cells and increased KI occurrence from undetectable to 4% in CD4 lymphocytes. Regardless of HDR efficiency, sorted cells were completely protected from X4 and R5 strains of HIV-1 and capable of expanding during acute viral replication. Thus, the developed CRISPR/Cas9 platform opens up new possibilities for HIV therapy based on protective peptide KI that, in primary human cells, had previously been considered inefficient.AUTHOR SUMMARYHIV is a human lentivirus that infects CD4-positive immune cells and, when left untreated, manifests in the fatal disease known as acquired immunodeficiency syndrome. Even after suppression with antivirals, HIV persists in the organism as a latent provirus. One way to decrease the viral reservoir is to engineer CD4 lymphocytes that are genetically resistant to HIV-1 infection via entry molecule knockout or expression of different antiviral genes. Peptides from the heptad repeat (HR) domain of gp41 are potent inhibitors of HIV-1 fusion, especially when designed to express on the cell surface. Individual gp41 peptides encoded by therapeutic lentiviral vectors have been evaluated and some have entered clinical trials. However, a CRISPR/Cas9-based gp41 peptide delivery platform that operates through concomitant target gene modification has not yet been developed due to low knock-in (KI) rates in primary cells. Here, we systematically evaluated the antiviral activity of different HR2-peptides cloned into the shortest carrier molecule, CD52. The resulting small-size transgene constructs encoding selected peptides, in combination with improvements to enhance donor vector nuclear import, helped to overcome precise editing restrictions in CD4 lymphocytes. Using KI into CXCR4, we demonstrated different options for target gene modification, effectively protecting edited cells against HIV-1.